| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/04/2004 | EP1385870A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |
| 02/04/2004 | EP1385861A2 Compositions and methods relating to lung specific genes and proteins |
| 02/04/2004 | EP1385857A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
| 02/04/2004 | EP1385854A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 02/04/2004 | EP1385852A1 Compounds and methods for inhibiting mrp1 |
| 02/04/2004 | EP1385849A1 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists |
| 02/04/2004 | EP1385848A2 Phtalazinones derivatives useful as pde4/7 inhibitors |
| 02/04/2004 | EP1385845A1 N-aroyl cyclic amines |
| 02/04/2004 | EP1385843A1 Arylindenopyridines with pde inhibiting activity |
| 02/04/2004 | EP1385842A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/04/2004 | EP1385841A1 Sulfonamides |
| 02/04/2004 | EP1385840A1 Sulfonamides |
| 02/04/2004 | EP1385839A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/04/2004 | EP1385837A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors |
| 02/04/2004 | EP1385836A2 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/04/2004 | EP1385835A1 Benzoxazinone derivatives for use in the treatment of angiogenesis |
| 02/04/2004 | EP1385825A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives |
| 02/04/2004 | EP1385823A1 Novel guanidino compounds |
| 02/04/2004 | EP1385822A1 Aminopyrrolidine sulfonamides as serine protease inhibitors |
| 02/04/2004 | EP1385821A2 Novel anti-adhesive compounds and uses thereof |
| 02/04/2004 | EP1385577A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 02/04/2004 | EP1385548A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/04/2004 | EP1385546A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| 02/04/2004 | EP1385536A2 Preparations containing a combination of vitamin e and afamin |
| 02/04/2004 | EP1385535A2 Modified fvii in treatment of ards |
| 02/04/2004 | EP1385534A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 02/04/2004 | EP1385533A1 Module of pd-1 interactions with its ligands |
| 02/04/2004 | EP1385531A2 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| 02/04/2004 | EP1385524A1 Pyrazolopyrimidines as therapeutic agents |
| 02/04/2004 | EP1385522A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 02/04/2004 | EP1385514A1 Spiroindene and spiroindane compounds |
| 02/04/2004 | EP1385513A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 02/04/2004 | EP1385512A2 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 02/04/2004 | EP1385508A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/04/2004 | EP1385507A1 Sulfonamides |
| 02/04/2004 | EP1385506A2 Acylated piperidine derivates as melanocortin-4 receptor agonists |
| 02/04/2004 | EP1385505A2 Acne treatment |
| 02/04/2004 | EP1385504A1 Method of inhibiting adhesion formation |
| 02/04/2004 | EP1385498A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 02/04/2004 | EP1385496A2 Use of compositions for treating rosacea |
| 02/04/2004 | EP1385495A2 Sulfonamides |
| 02/04/2004 | EP1385494A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs |
| 02/04/2004 | EP1385493A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties |
| 02/04/2004 | EP1385489A1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 02/04/2004 | EP1385480A1 Liposomes |
| 02/04/2004 | EP1296947B1 $g(A) CRYSTALLINE FORM OF PERINDOPRIL TERT-BUTYLAMINE SALT |
| 02/04/2004 | EP1216041B1 High lipid diet |
| 02/04/2004 | EP1196409B1 Respiratory syncytial virus replication inhibitors |
| 02/04/2004 | EP1189615B1 Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines |
| 02/04/2004 | EP1115697B1 Unsaturated hydroximic acid derivatives as parp inhibitors |
| 02/04/2004 | EP1076650B1 Aryl fused azapolycyclic compounds |
| 02/04/2004 | EP1030839B1 Use of alkylated iminosugars to treat multidrug resistance |
| 02/04/2004 | EP1021196B1 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 02/04/2004 | EP1007055B1 Use of amifostine |
| 02/04/2004 | EP0992495B1 Process for obtaining quinapryl hydrochloride and solvates useful for isolating and purifying quinapryl hydrochloride |
| 02/04/2004 | EP0966293B1 Medicine for promoting cicatrization and containing thrombocytes |
| 02/04/2004 | EP0925067B1 Graft from submucosal intestinal tissue for repairing neurological tissue |
| 02/04/2004 | EP0698094B1 Bmp-11 compositions |
| 02/04/2004 | CN1473163A Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors |
| 02/04/2004 | CN1473161A Pyrazole compounds as protein kinase inhibitors |
| 02/04/2004 | CN1473156A Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
| 02/04/2004 | CN1473154A Phthalazinone derivatives |
| 02/04/2004 | CN1473151A Crystalline forms of fluvastatin sodium |
| 02/04/2004 | CN1473150A Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 02/04/2004 | CN1473148A Novel crystals of N-hydroxy-2(S)-methyl-5-ethoxymethoxy-4(S)-[N-(4- phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing crystals as active ingredient |
| 02/04/2004 | CN1473061A Antithrombotic compositions |
| 02/04/2004 | CN1473055A Methods for enhancing efficacy of cytotoxic agents through use of HSP90 inhibitors |
| 02/04/2004 | CN1473052A PSGL-1 regulator |
| 02/04/2004 | CN1473050A Use of long pentraxin PTX3 for treatment of diseases caused by altered activation of growth factor FGF-2 |
| 02/04/2004 | CN1473047A Method for treating hypogonadism |
| 02/04/2004 | CN1473046A Improved treatment |
| 02/04/2004 | CN1473045A Process for preparation of dinapsoline |
| 02/04/2004 | CN1473043A Method for treating allergies using substituted pyrazoles |
| 02/04/2004 | CN1473042A Medical compositions |
| 02/04/2004 | CN1473040A Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity |
| 02/04/2004 | CN1471975A Immune adjusting agent |
| 02/04/2004 | CN1471974A Anti-inflammatory agent |
| 02/04/2004 | CN1137133C Preparation of sterol and dihydro-sterol ester |
| 02/04/2004 | CN1137123C Azolo triazizes and pyrimidines |
| 02/04/2004 | CN1137100C Tricyclic compounds capable of inhibiting tyrosine kinases of epidermal growth factor receptor family |
| 02/04/2004 | CN1137083C New benzocyclobutane compounds, process for their preparation and pharmaceutical compositions containing them |
| 02/04/2004 | CN1136865C Wound curing and swelling-eliminating traditional Chinese medicine ointment |
| 02/04/2004 | CN1136856C Use of strontium salts for production of pharmaceutical compositions intended for treatment of arthrosis |
| 02/04/2004 | CN1136844C Anti-AIDS medicine composition and its application |
| 02/03/2004 | US6686493 Antiproliferation agent; antiinflammatory agents; side effect reduction |
| 02/03/2004 | US6686471 Process and intermediates for growth hormone secretagogues |
| 02/03/2004 | US6686467 Inhibitors of the production of cytokines such as tumour necrosis factor (hereinafter tnf), for example tnf alpha , and various members of the interleukin (hereinafter il) family, for example il-1, il-6 and il-8 |
| 02/03/2004 | US6686388 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 02/03/2004 | US6686386 Combating photoinduced or chronological ageing of skin with retenoic acid receptor agonist |
| 02/03/2004 | US6686385 Anhydro sugar derivatives of indolocarbazoles |
| 02/03/2004 | US6686384 2-anilinophenyl-substituted; inhibition of the na+/h+ exchanger |
| 02/03/2004 | US6686381 Compounds that antagonize neuropeptide y at the y5 receptor subtype represent an approach to the treatment of eating disorders such as obesity and hyperphagia |
| 02/03/2004 | US6686373 Analgesics; antiinflammatory agent |
| 02/03/2004 | US6686372 Selective β3 adrenergic agonists |
| 02/03/2004 | US6686370 8-(4,4-bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazospiro(4.5) decan-4-one, for example; treating pain with reduced side effects of opioid analgesics; affinity for opioid receptor-like (orl1) receptor |
| 02/03/2004 | US6686367 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 02/03/2004 | US6686363 Effective against multi-resistant bacteria |
| 02/03/2004 | US6686362 Indolinone derivatives |
| 02/03/2004 | US6686358 Anticoagulants; cardoviscular disorders |